Company news

Arcutis Biotherapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis

August 24, 2021

Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

August 22, 2021

Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update

August 4, 2021

Arcutis Announces Additions to its Investor Relations and Communications Team

August 1, 2021

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis

July 20, 2021

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis

July 11, 2021

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

June 30, 2021

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

June 22, 2021

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

June 8, 2021

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

May 31, 2021

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021

Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years

April 11, 2021

Arcutis Announces Updates to its Executive Team

March 25, 2021

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

March 17, 2021

Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff

February 17, 2021

Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

February 15, 2021

Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock

February 1, 2021

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

January 31, 2021

Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

January 19, 2021

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

January 12, 2021

Matthew Moore Joins Arcutis as Chief Business Officer

January 10, 2021

Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

December 6, 2020

Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020

December 1, 2020

Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

November 30, 2020

Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis

November 22, 2020

Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

Arcutis Announces Appointment of Terrie Curran to Board of Directors

November 3, 2020

Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis

November 1, 2020

Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences

October 28, 2020

Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

October 25, 2020

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

October 5, 2020

Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock

September 30, 2020

Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

September 28, 2020

Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

September 15, 2020

Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA

September 7, 2020

Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update

August 10, 2020

Bethany Dudek Joins Arcutis as Vice President of Quality

August 3, 2020

Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer

July 26, 2020

Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis

July 19, 2020

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

July 12, 2020

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

June 21, 2020

Ayisha Jeter Joins Arcutis as Vice President of Market Access

May 31, 2020

Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations

May 26, 2020

Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update

May 11, 2020

Halley E. Gilbert Appointed to Arcutis Board of Directors

April 26, 2020

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema

April 20, 2020

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

March 22, 2020

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

March 15, 2020

Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications

March 4, 2020

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting

March 2, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 27 decks. Every deck is listed under its year.